ReviewFrontiers in immunology2026
Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abscopal effect, defined as the regression of non-irradiated tumors following localized radiotherapy (RT), represents one of the most intriguing manifestations of systemic antitumor immunity. Although traditionally considered a rare and unpredictable phenomenon, increasing evidence indicates that the abscopal effect is an immune-mediated process initiated by RT-induced immunogenic cell death. In addition to directly eliminating tumor cells, RT promotes the release of tumor-associated antigens and danger-associated molecular patterns, activates antigen-presenting cells, and primes tumor-specific T-cell responses, thereby triggering systemic immune surveillance. The development of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has substantially enhanced the likelihood of inducing abscopal responses by sustaining antitumor immunity and overcoming tumor-induced immune suppression. As a result, the abscopal effect has evolved from an anecdotal clinical observation into a promising strategy for systemic cancer treatment. However, its clinical application remains limited by tumor heterogeneity, the immunosuppressive tumor microenvironment, uncertainties regarding optimal radiation dose, fractionation, and treatment sequencing, as well as the lack of reliable predictive biomarkers. In this review, we summarize the current understanding of the biological mechanisms underlying the abscopal effect, discuss its reciprocal interaction with immunotherapy, and evaluate recent advances in radio-immunotherapy. We also highlight the major challenges that impede clinical translation and discuss future strategies for biomarker development, treatment optimization, and precision radio-immunotherapy. Overall, this review provides a comprehensive overview of the current landscape of the abscopal effect and offers perspectives on its development as a predictable and clinically applicable therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.